Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), is a nonapeptide hormone synthesized in hypothalamic nuclei and released from the posterior pituitary in response to increased plasma osmolality (>295 mOsm/kg), decreased blood volume (>10% loss), or stress. It acts primarily via V2 receptors in renal collecting ducts to promote water reabsorption and via V1 receptors on vascular smooth muscle to cause vasoconstriction. An evolutionarily ancient water-conservation mechanism, chronic AVP elevation in modern contexts contributes to hypertension, edema, and metabolic dysfunction.
Think of AVP as the emergency water-rationing officer in a city's water department. In ancestral drought conditions—walking across savannas for days without finding water—this officer would receive an urgent signal ("osmolality rising!") and immediately issue two commands: First, to the kidney's filtration plants (V2 receptors): "Insert more water-recapture channels (aquaporin-2) into the collection pipes—we cannot afford to lose a single drop in the urine." Second, to the arterial highways (V1 receptors): "Constrict all blood vessels to maintain blood pressure even as total fluid volume drops—we must keep perfusing the brain." This dual strategy kept our ancestors alive during dehydration crises lasting hours to days. But in modern life, this emergency officer is on chronic high alert—responding to inadequate daily water intake, high sodium processed foods, chronic stress, and metabolic dysfunction. The result? The "emergency" water-retention program runs 24/7, contributing to persistently elevated blood pressure (chronic vasoconstriction) and fluid retention in tissues (edema). What saved lives acutely now damages cardiovascular health chronically.
AVP is synthesized as a prohormone in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus. The prohormone travels via axonal transport to the posterior pituitary where it is cleaved and stored in vesicles. Release is triggered by:
Osmotic pathway:
- Osmoreceptors in circumventricular organs (OVLT, subfornical organ) detect plasma osmolality >295 mOsm/kg
- Signal transmitted to SON/PVN → Ca²⁺ influx → vesicle fusion → AVP release into systemic circulation
Volume/pressure pathway:
- Baroreceptors in carotid sinus and aortic arch detect blood volume loss >10%
- Signal via vagal afferents → nucleus tractus solitarius → disinhibition of SON/PVN → AVP release
Stress pathway:
- CRH release from PVN parvocellular neurons → co-stimulates AVP release
- Synergistic with cortisol stress response
Renal effects (V2 receptor - Gs-coupled):
graph TD
A[AVP binds V2 receptor on basolateral membrane] --> B[Gs activation]
B --> C["Adenylyl cyclase → cAMP ↑"]
C --> D[PKA activation]
D --> E[Phosphorylation of aquaporin-2 storage vesicles]
E --> F[Vesicle fusion with apical membrane]
F --> G[Water reabsorption from collecting duct lumen]
D --> H[Transcriptional upregulation of AQP2 gene]
G --> I[Concentrated urine, water retention]
Vascular effects (V1a receptor - Gq-coupled):
- AVP → V1a receptor on vascular smooth muscle → phospholipase C activation → IP3 + DAG
- IP3 → Ca²⁺ release from sarcoplasmic reticulum → calmodulin-myosin light chain kinase activation
- Smooth muscle contraction → vasoconstriction → blood pressure elevation
Hepatic effects (V1a receptor):
- AVP → V1a in hepatocytes → glycogenolysis → glucose release (synergistic with stress response)
Metabolic threshold:
Normal plasma AVP: 1-5 pg/mL (fasting, euhydrated state)
Dehydration response: rises to 10-20 pg/mL when plasma osmolality >295 mOsm/kg
Pathological elevation: chronic levels >7 pg/mL associated with hypertension and metabolic syndrome
AVP represents a textbook example of Evolutionary mismatch—a rapid-response survival mechanism for acute dehydration crises that becomes pathological when chronically activated in modern environments. In hunter-gatherer contexts, episodic water scarcity lasting hours to days required aggressive water conservation. Modern humans rarely face true dehydration emergencies, yet chronic suboptimal hydration (drinking only when thirsty, high sodium intake, caffeinated beverages, processed foods) maintains AVP in a persistently elevated state.
Clinical relevance in cPNI practice:
Hypertension: Chronic AVP elevation contributes to essential hypertension via sustained V1a-mediated vasoconstriction and increased sodium retention. Approximately 30% of hypertensive patients show elevated plasma AVP (>7 pg/mL) compared to normotensive controls (<5 pg/mL). This is compounded when occurring alongside insulin resistance and leptin resistance (the metabolic components of CoVesity).
Metabolic dysfunction: AVP potentiates HSR (hypoxia stress response) and interacts with HIF-1 signaling—both promote glycolysis and insulin resistance. Chronically elevated AVP correlates with visceral adiposity and NAFLD development. The Selfish Brain theory context: AVP-driven water retention and vasoconstriction prioritize brain perfusion at the expense of peripheral metabolic health.
Heart failure and edema: In decompensated heart failure, the body misinterprets reduced cardiac output as volume depletion → inappropriate AVP release → worsening fluid overload and hyponatremia (dilutional). V2 receptor antagonists (vaptans) target this mechanism.
SIADH (Syndrome of Inappropriate ADH): Ectopic AVP production (small-cell lung cancer, CNS disorders) or enhanced renal sensitivity causes hyponatremia (<135 mmol/L) and concentrated urine (>100 mOsm/kg) despite low plasma osmolality.
Intervention implications:
- Adequate hydration: 30-35 mL/kg/day water intake can normalize AVP secretion patterns
- Sodium moderation: Reduce processed food intake to decrease osmotic AVP triggers
- Intermittent Living application: Strategic water loading and periodic mild dehydration may restore AVP sensitivity
- Address metabolic dysfunction: Reverse insulin resistance to break positive feedback loops involving AVP, cortisol, and sympathetic tone
- Stress management: Chronic psychological stress via CRH pathway chronically elevates AVP independent of osmotic status
- Synthesized in hypothalamic supraoptic and paraventricular nuclei, stored and released from posterior pituitary
- Normal plasma concentration 1-5 pg/mL; rises to 10-20 pg/mL during dehydration (osmolality >295 mOsm/kg)
- Half-life in circulation: 10-20 minutes (rapid on/off kinetics for acute regulation)
- V2 receptors (kidney collecting ducts) mediate water reabsorption via aquaporin-2 insertion
- V1a receptors (vascular smooth muscle) mediate vasoconstriction and blood pressure elevation
- V1b receptors (anterior pituitary) potentiate ACTH release during stress
- Chronic elevation (>7 pg/mL) associated with hypertension, metabolic syndrome, and cardiovascular disease
- Alcohol inhibits AVP release → diuresis (explains dehydration after drinking)
- MDMA/ecstasy stimulates massive AVP release → hyponatremia and cerebral edema risk
- Evolutionary role: enabled survival during multi-day dehydration events; maladaptive when chronically activated
- Copeptin (stable AVP precursor fragment) used clinically as biomarker—more stable than AVP itself
- Elevated AVP blunts natriuretic peptide effectiveness (ANP/BNP), contributing to treatment-resistant hypertension
- Dehydration — primary evolutionary trigger for AVP release; modern chronic suboptimal hydration maintains elevated AVP
- H2O — inadequate water intake (most common modern trigger for AVP elevation)
- sodium — high dietary sodium increases plasma osmolality, triggering AVP release and retention
- hypertension — chronic AVP-mediated vasoconstriction (V1a) and sodium/water retention contribute to elevated blood pressure
- edema — excessive AVP-driven water reabsorption causes tissue fluid accumulation
- Hypothalamus — site of AVP synthesis in supraoptic and paraventricular nuclei
- posterior pituitary — storage and release site for AVP into systemic circulation
- Circumventricular organs — contain osmoreceptors (OVLT) that detect changes in plasma osmolality
- HSR — hypoxia stress response synergizes with AVP in metabolic dysfunction and insulin resistance
- HIF-1 — hypoxia-inducible factor interacts with AVP signaling to promote glycolysis and vasoconstriction
- insulin resistance — chronic AVP elevation contributes to metabolic syndrome and impaired glucose disposal
- leptin resistance — part of the CoVesity triad alongside insulin resistance and AVP dysregulation
- Cortisol — CRH co-stimulates AVP release during stress; both hormones synergize in stress response
- CRH — corticotropin-releasing hormone from PVN stimulates both ACTH and AVP secretion
- Evolutionary mismatch — adaptive acute dehydration response becomes chronic disease mechanism in modern context
- CoVesity — AVP dysregulation as component of obesity-hypertension-metabolic syndrome cluster
- Aldosterone — works synergistically with AVP to retain sodium and water in kidney
- renin — RAA system and AVP both activated by volume depletion; additive effects on blood pressure
- Ang II — angiotensin II stimulates AVP release and shares vasoconstrictor effects
- kidney — primary target organ where V2 receptors mediate water reabsorption in collecting ducts
- chronic stress — psychological stressors chronically elevate AVP via CRH pathway independent of hydration status
- metabolic syndrome — AVP elevation correlates with visceral adiposity, hyperglycemia, and dyslipidemia
- Anaerobic Glycolysis — AVP promotes via HIF-1 activation, contributing to metabolic inflexibility
- NAFLD — non-alcoholic fatty liver disease associated with chronic AVP elevation and insulin resistance
- Selfish Brain — AVP-mediated vasoconstriction and water retention prioritize cerebral perfusion over peripheral metabolic health
- Module 1
- Module 2
- Module 3